CAPZA2
Overview
CAPZA2 (F-actin-capping protein subunit alpha-2) encodes a subunit of the F-actin capping protein complex, which regulates actin filament dynamics. In cancer genomics, CAPZA2 was identified as a fusion partner of MET in a novel gene fusion detected in lung adenocarcinoma, adding it to the growing list of MET fusion partners with potential oncogenic activity.
Alterations observed in the corpus
- CAPZA2 (capping protein alpha 2) was identified as a fusion partner in a novel MET-CAPZA2 fusion gene detected in lung adenocarcinoma PMID:27158780.
Cancer types (linked)
- LUAD: MET-CAPZA2 fusion detected in lung adenocarcinoma in the TCGA Pan-Lung analysis; MET amplifications were enriched in tumors lacking other RTK/Ras/Raf activating events PMID:27158780.
Co-occurrence and mutual exclusivity
- MET-CAPZA2 fusion co-occurs in the context of oncogene-negative lung ADCs; previously reported KIF5B-MET fusion also found in same cohort PMID:27158780.
Therapeutic relevance
- MET fusions including MET-CAPZA2 represent candidate actionable alterations in oncogene-negative lung ADC, which constitutes ~37% of the TCGA lung ADC cohort PMID:27158780.
Open questions
- Functional oncogenicity of MET-CAPZA2 fusion has not been characterized; it is unclear whether this fusion is kinase-activating and responsive to MET inhibitors PMID:27158780.
Sources
This page was processed by crosslinker on 2026-05-14.